Full-Time
Executive Director
Commercial Analytics & Operations
Posted on 8/26/2025
Halozyme
501-1,000 employees
Licenses ENHANZE enzyme for injectable delivery
Compensation Overview
$225k - $330k/yr
Lawrence Township, NJ, USA
In Person
 Business & Strategy (2) |
|---|
| , |
- Bachelor’s degree with minimum of 18 years of pharmaceutical commercial analytics and operations experience (an equivalent combination of experience and education may be considered)
- Experience supporting commercial, medical, Finance and other noncommercial applications
- Advanced understanding of data warehouse and management architecture
- Experience with Specialty Pharmacy/Distributor data and/or IQVIA/Symphony datasets
- Experience as a technical business partner supporting key business areas
- Ability to innovate through identifying potential solutions while considering potential trade spaces
- Working knowledge and proficiency with business applications, languages, operating systems and business intelligence tools: SQL, Access, Excel, VBA, Tableau, Power BI, MicroStrategy, Qlik, Veeva My Insights and HTML, Salesforce, Veeva Vault, Microsoft Office, Windows Server, Command line scripting, sFTP and Apple IOs
- Lead the strategy and execution of Commercial Analytics and Insight Generation, Incentive Compensation Programs, Demand Forecast, CRM platforms and the advancement of all Commercial applications, platforms, systems, data warehouse, dashboards, reporting and Master Data Management processes
- Harness the rich commercial data and lead, advance and evolve the overall commercial enterprise analytics, reporting, and insights (equally supporting Market Access, Marketing and Sales)
- Strategically plan and lead the Commercial Analytics and Commercial/Sales operations budgets, including negotiating contracts with vendors and managing vendor performance and deliverables
- Lead the Commercial Analytics team and vendors to design, build, and maintain all Marketing, Market Access, and Sales reporting on multiple platforms, ultimately delivering actionable insights
- Bring forward new evolutions and tools to support enhanced decision making and impact in front of customers
- Lead Commercial Analytics team to develop robust analytics and reporting (weekly/monthly) to monitor and assess key pieces of the Market Access go to market model (e.g. payers, payer contracts, specialty pharmacy, copay program…) and deliver actionable insights and opportunities
- Lead team to development of forecast models in partnership with Sales, Marketing, Market Access, and Finance
- Lead team to deliver enhancements in Incentive Compensation and Contests/Kickers design, build, automation, and monitoring to align with the brand strategy and forecast as well as bring innovative and accurate strategies and models; Via both the Commercial Analytics Team and Vendors
- Establish governance for proper use and administration of commercial data, forecasting, and incentive compensation
- Lead and support Sales Operations activities including fleet management, sample management, and CRM optimization and administration
- Regularly assess roles, responsibilities, and priorities of all direct reports, budget, and contracted vendors and adjust as necessary to focus time and resources against key commercial strategies and priorities
- Develops and implements compliance measures
- Partners with IT and vendors to evaluate, recommend, and implement emerging machine learning and Artificial Intelligence technologies into analytic platforms and CRM/Dashboard reporting- develop a 3 year roadmap for data and reporting across the commercial enterprise
Halozyme focuses on developing and commercializing ENHANZE, a recombinant hyaluronidase enzyme that temporarily breaks down hyaluronan in subcutaneous tissue to facilitate the delivery of injectable drugs. Through licensing its ENHANZE technology to large pharmaceutical companies, Halozyme enables partners to administer higher-volume or less painful subcutaneous injections. The company earns revenue from upfront licensing fees, milestone payments, and royalties on sales of drugs that use ENHANZE. What sets Halozyme apart is its B2B model centered on a proven collaboration strategy with major pharma players like Roche and Janssen, a track record of FDA-approved fixed-dose subcutaneous combinations, and a focused, royalty-based revenue stream tied to partner products. Halozyme’s goal is to expand access to subcutaneous drug delivery by partnering with more pharmaceutical companies and increasing the number of ENHANZE-enabled therapies registered and sold.
Company Size
501-1,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
1998
Simplify's Take
What believers are saying
- Q1 2026 royalties hit $241M, up 43% YoY, driven by DARZALEX SC and VYVGART Hytrulo.
- 2026 guidance projects $1.13B-$1.17B royalties, exceeding $1B for first time.
- New Vertex $15M Hypercon deal and GSK/Oruka pacts add milestone and royalty streams.
What critics are saying
- DARZALEX Faspro and VYVGART Hytrulo comprise over 40% royalties; safety recalls slash 15-25% revenue.
- Pfizer's 2026 trastuzumab biosimilar erodes Roche Phesgo royalties by 10-15% within 12 months.
- Collaboration revenue drops 70% YoY to $5.6M; misses three 2026 deals amid pharma cuts.
What makes Halozyme unique
- ENHANZE enables subcutaneous delivery for 10 products across 100 markets using rHuPH20 enzyme.
- Hypercon microparticle technology hyperconcentrates biologics for at-home administration.
- Partners include Roche, Janssen, argenx, Vertex, GSK, and Oruka for drug-device combos.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Employee Stock Purchase Program
401(k) Company Match
Professional Development Budget
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↓ -5%2 year growth
↓ -5%Paragon Capital Management has purchased 18,920 shares in Halozyme Therapeutics, valued at approximately $1.27 million, during the fourth quarter of 2025, according to a recent SEC filing. The investment represents a new stake in the San Diego-based biopharmaceutical company. Halozyme specialises in drug delivery technologies, including its ENHANZE platform. Several other institutional investors, including Empowered Funds, Acadian Asset Management, HSBC Holdings and EverSource Wealth Advisors, have also recently adjusted their positions in the company. The investment signals institutional confidence in Halozyme's growth prospects and drug delivery innovations within the pharmaceutical sector.
SentinelOne, an AI-powered cybersecurity platform provider, is trading at $13.44 per share with a market capitalisation of $4.59 billion. The company's platform autonomously prevents, detects and responds to threats across endpoints, cloud workloads and identity systems. SentinelOne demonstrates strong fundamentals with annual recurring revenue trends showing steady long-term contract flow. The company projects 20% revenue growth over the next 12 months, maintaining momentum from the previous two years. Its gross margin of 74.1% provides financial flexibility for marketing investments and product development. The stock trades at 3.7x forward price-to-sales. Meanwhile, Vishay Intertechnology faces headwinds with declining sales and margin pressures. Halozyme Therapeutics develops technology enabling subcutaneous drug delivery.
Halozyme Therapeutics, a small-cap biotech company known for its ENHANZE technology that transforms hours-long intravenous infusions into minutes-long subcutaneous injections, has been identified as a stock worth watching for long-term investors. The company has a market capitalisation of $7.53 billion. In contrast, two small-cap stocks appear less promising. Olaplex, the TikTok-famous hair care brand, has seen revenue decline 15.6% annually over the past three years, with earnings per share falling faster than revenue. The company trades at 23.1x forward P/E. Resideo Technologies, a manufacturer of home comfort and security products, has demonstrated flat earnings per share over five years despite revenue growth, with declining free cash flow margins and eroding returns on capital.
Halozyme announces global collaboration and license agreement with Vertex Pharmaceuticals for Hypercon(TM) technology. 8 April 2026 Halozyme Therapeutics, Inc. today announced its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals Incorporated ("Vertex"). Under the collaboration, Vertex has licensed Halozyme's Hypercon(TM) technology for use in up to three drug targets. Hypercon(TM) is an innovative microparticle technology that allows for hyperconcentration of drugs and biologics, thus reducing injection volume for the same dosage and enabling convenient, at-home administration. "This collaboration with Vertex underscores the versatility and potential of our Hypercon technology to enable small volume, patient-delivered next-generation biologics," said Helen Torley, President and Chief Executive Officer of Halozyme. "Vertex is a proven innovator with deep expertise, and we believe Hypercon can play an important role in supporting improved ease of patient access to targeted biologics that have the potential to advance innovation for patients with serious diseases." "We are pleased to add Halozyme's Hypercon drug delivery technology to our toolbox as we pursue transformative therapies for patients with serious diseases," said Mark Bunnage, D.Phil., Executive Vice President and Chief Scientific Officer of Vertex Pharmaceuticals. "We look forward to exploring the full potential of this technology across our programs of interest." Under the terms of the exclusive agreement, Vertex will make a $15 million upfront payment to Halozyme and potential future milestone payments. Halozyme will also be entitled to royalties on net sales of products developed using the Hypercon(TM) technology. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE(R) drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE(R) has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V. and Skye Bioscience. Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon(TM) and Surf Bio's hyperconcentration technology. Hypercon(TM) is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at-home and healthcare-provider settings. The addition of Surf Bio's polymer-based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon(TM) and Surf Bio's technology complement ENHANZE(R) by enabling creation and delivery of highly concentrated biologics. The Hypercon(TM) technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly, argenx and Vertex Pharmaceuticals. Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex(R) and XYOSTED(R), partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc. Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility. Forward-Looking Statements In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning royalty revenue growth, potential new partnerships and innovations, the possible benefits and attributes of the Hypercon(TM) technology, including the potential to reduce injection volume for the same dosage of drugs and biologics and possibly enabling administration in at-home and healthcare-provider settings and statements concerning certain other potential benefits of the Hypercon(TM) technology including facilitating administration of injectable medications through subcutaneous delivery by enabling creation and delivery of highly concentrated biologics and potentially lowering the treatment burden, easing treatment access and improving the treatment experience for patients. These forward-looking statements also include statements regarding the product development and commercialization efforts of Hypercon's collaboration partner (including the potential regulatory approval and launch of such products as a result of such efforts and the potential future market opportunity for such products) and Hypercon's potential receipt of upfront payments and payments associated with achievement of certain development, regulatory and sales-based milestones, and royalties on sales of commercialized products. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue" and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including risks and uncertainties concerning whether payments due to Hypercon under the collaboration agreement will be received and whether development, regulatory and sales-based milestones will be achieved, uncertainties concerning whether collaborative products are ultimately developed, approved or commercialized and the potential future market for such products, unexpected levels of revenue growth, expenditures and costs, unexpected results or delays in development and regulatory review, unexpected regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release. Tram Bui VP, Investor Relations and Corporate Communications 609-333-7668 [email protected] Sydney Charlton Teneo 917-972-8407 [email protected]
Halozyme inks license agreement with Vertex. 8 April 2026 San Diego, USA-based Halozyme Therapeutics (Nasdaq: HALO) late yesterday announced it has entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals (Nasdaq: VRTX). This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 17 November 2025 25 April 2025 14 September 2017 Company news directory. Companies featured in this story. Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 8 April 2026 7 April 2026 Company spotlight. A clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases characterized by abnormal appetite and metabolic disorders. More features in pharmaceutical. 8 April 2026 7 April 2026